

4-26-04

04-29-2004



102734419

Form PTO-1595 (Rev. 10/02) R
OMB No. 0651-0027 (exp. 6/30/2005)
Tab settings

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies): Wells Fargo Foothill, Inc.</p> <p>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and address of receiving party(ies) Name: <u>Nabi Biopharmaceuticals</u> Internal Address: _____ _____ _____ Street Address: <u>5800 Park of Commerce Blvd, NW</u> _____ _____ City: <u>Boca Raton</u> State: <u>FL</u> Zip: <u>33487</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input checked="" type="checkbox"/> Other <u>Termination of Security</u></p> <p>Execution Date: <u>3/26/04</u></p>	

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____

<p>A. Patent Application No.(s) _____ <u>See attached</u></p>	<p>B. Patent No.(s) _____ <u>See attached</u></p>
---	---

Additional numbers attached? Yes No

<p>5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Yolanda Lyle</u> Internal Address: <u>Nutter, McClennen & Fish, LLP</u> _____ _____ Street Address: <u>World Trade Center West</u> <u>155 Seaport Boulevard</u> City: <u>Boston</u> State: <u>MA</u> Zip: <u>02210</u></p>	<p>6. Total number of applications and patents involved: <u>15</u></p> <p>7. Total fee (37 CFR 3.41).....\$ <u>600</u> <input checked="" type="checkbox"/> Enclosed <input type="checkbox"/> Authorized to be charged to deposit account</p> <p>8. Deposit account number: <u>141449</u></p>
--	--

DO NOT USE THIS SPACE

9. Signature.

<p><u>Renee' Diana Sanft</u> Name of Person Signing</p>	<p> Signature</p>	<p><u>4/28/04</u> Date</p>
---	-----------------------	--------------------------------

Total number of pages including cover sheet, attachments, and documents: 50

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

04/28/2004 MGETACHE 00000003 6232082

01 FC:8021

600.00 DP

PATENT
REEL: 015259 FRAME: 0383

TERMINATION OF SECURITY INTEREST

WHEREAS, NABI BIOPHARMACEUTICALS, a Delaware corporation ("NABI") had granted to WELLS FARGO FOOTHILL, INC., a California corporation (the "Bank") a security interest (the "Security Interest") in the patents described on Schedule A hereto (the "Patents") and the goodwill associated therewith under that certain Patent Security Agreement dated as of June 18, 2003, by and between NABI and the Bank; and

WHEREAS, notice of said Security Interest was recorded with the United States Patent and Trademark Office on August 12, 2003, Reel 014357, Frame 0486; and


WHEREAS, the indebtedness secured by said security interest has been paid in full.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Bank hereby releases and discharges and acknowledges the release and discharge of the aforementioned Security Interest.

WITNESS, the execution hereof as an instrument under seal as of this 26th day of March, 2004.

WELLS FARGO FOOTHILL, INC.

Dated: 3/26/04

By: 
Name: DENNIS J. KEENAN
Title: V.P.

NABI PATENT SCHEDULE

UNITED STATES

Pending Applications:

Patent Application No.	Filing Date	Title
20030113350	9/19/01	Glycoconjugate Vaccines for Use in Immune-Compromised Populations
20020004208	12/30/02	Hapten-Carrier Conjugates for Treating and Preventing Nicotine Addiction

Issued Patents:

Patent Issue Number	Filing Date	Title
6,232,082	12/1/98	Hapten-Carrier Conjugates for Treating and Preventing Nicotine Addiction
6,294,177	5/10/99	Staphylococcus Aureus Antigen-Containing Whole Cell Vaccine
6,355,625	9/14/99	Compositions of Beta-Glucans and Specific 1G1V
6,518,031	2/16/01	Hapten-Carrier Conjugates for Treating and Preventing Nicotine Addiction
6,194,161	6/22/98	Staphylococcus Aureus Antigen
6,537,559	9/24/01	Staphylococcus Aureus Antigen-Containing Whole Cell Vaccine
6,518,031	2/16/01	Hapten-Carrier Conjugates for Treating and Preventing Nicotine Addiction
6,194,161	6/22/98	Staphylococcus Aureus Antigen
6,537,559	9/24/01	Staphylococcus Aureus Antigen-Containing Whole Cell Vaccine
5,770,208	9/11/96	Staphylococcus Aureus Antigen

5,866,140	12/22/94	Type I Surface Antigen Associated with Staphylococcus Epidermidis
5,961,975	6/7/95	Type I Surface Antigen Associated with Staphylococcus Epidermidis
5,843,912	8/23/95	Ring Expanded Nucleosides and Nucleotides

9477230.1

RECORDED: 04/26/2004

PATENT
REEL: 015259 FRAME: 0386